This page has beta status

CMST COST Action CM0602
Inhibitors of angiogenesis: design, synthesis and biological exploitation (ANGIOKEM)

Excessive or insufficient angiogenesis (new blood vessel formation) is connected with many human diseases, cancer included. For effective disease intervention, interdisciplinary approach in the research is necessary. This COST Action focuses on networking of interdisciplinary oriented chemistry and biology researchers who are actively involved in rationale designing and development of small organic compounds with anti-angiogenic properties. Exchanges of information and presentations of experiences and skills from chemical and biological research will be performed for effective introduction, exploitation and improvement of modern methods for development of new angiogenic inhibitors. Meetings, short-term scientific missions, workshops, training schools and conference will ensure the expansion of effective cooperation in the development of new drug candidates.
Keywords: Inhibition of neovascularisation; lead compounds and drug design; treatment of cancer and other diseases; in silico predictions; multivalency in organic synthesis and biology

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Daniele PASSARELLA (IT)

Vice Chair of the Action:

Prof Marta SALISOVA (SK)

Science officer of the Action:

Dr Lucia FORZI

Administrative officer of the Action:

Ms Svetlana VOINOVA


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Progress Report

Download Progress Report as PDF


Download Poster as PDF


Action website:

* content provided by e-COST.
Data is synchronised once per night.


Last updated: 02 May 2011 top of page